Metabolic assessment in pure struvite stones formers: is it necessary?
Journal
Jornal brasileiro de nefrologia
ISSN: 2175-8239
Titre abrégé: J Bras Nefrol
Pays: Brazil
ID NLM: 9426946
Informations de publication
Date de publication:
Historique:
received:
25
05
2020
accepted:
02
11
2020
pubmed:
13
2
2021
medline:
19
8
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Magnesium ammonium phosphate stones (MAP), also known as struvite stones, are associated with urinary infection and impairment of renal unit. The aim of this study is to evaluate the urinary metabolic risk factors for recurrence of renal calculi in patients submitted to nephrectomy due to MAP stones. We retrospectively reviewed the charts of patients > 18 years old submitted to total nephrectomy due to pure MAP stones and pure calcium oxalate (CaOx) stones from July 2006 to July 2016. Urinary metabolic parameters were assessed through 24-hour urine exams ≥ 3 months after nephrectomy. Urinary metabolic parameters and new event related to lithiasis were compared. Twenty-eight and 39 patients were included in MAP and CaOx group, respectively. Abnormalities in 24-hour urine samples were similar between groups. Hypercalciuria occurred in 7.1 and 10.3% of patients in MAP and CaOx group, respectively (p = 0.66), whereas hypocitraturia was present in 65.2 and 59.0% of patients with MAP and CaOx group, respectively (p = 0.41). No significant difference in new events was found between MAP and CaOx groups (17.9 vs. 23.1%, respectively; p = 0.60). A 24-hour urine evaluation should be offered to patients submitted to nephrectomy due to pure MAP stones in order to detect metabolic risk, improve treatment, and prevent stone recurrence.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Magnesium ammonium phosphate stones (MAP), also known as struvite stones, are associated with urinary infection and impairment of renal unit. The aim of this study is to evaluate the urinary metabolic risk factors for recurrence of renal calculi in patients submitted to nephrectomy due to MAP stones.
METHODS
METHODS
We retrospectively reviewed the charts of patients > 18 years old submitted to total nephrectomy due to pure MAP stones and pure calcium oxalate (CaOx) stones from July 2006 to July 2016. Urinary metabolic parameters were assessed through 24-hour urine exams ≥ 3 months after nephrectomy. Urinary metabolic parameters and new event related to lithiasis were compared.
RESULTS
RESULTS
Twenty-eight and 39 patients were included in MAP and CaOx group, respectively. Abnormalities in 24-hour urine samples were similar between groups. Hypercalciuria occurred in 7.1 and 10.3% of patients in MAP and CaOx group, respectively (p = 0.66), whereas hypocitraturia was present in 65.2 and 59.0% of patients with MAP and CaOx group, respectively (p = 0.41). No significant difference in new events was found between MAP and CaOx groups (17.9 vs. 23.1%, respectively; p = 0.60).
CONCLUSION
CONCLUSIONS
A 24-hour urine evaluation should be offered to patients submitted to nephrectomy due to pure MAP stones in order to detect metabolic risk, improve treatment, and prevent stone recurrence.
Identifiants
pubmed: 33577639
pii: S0101-28002021005010301
doi: 10.1590/2175-8239-JBN-2020-0106
pmc: PMC8257276
pii:
doi:
Substances chimiques
Calcium Oxalate
2612HC57YE
Struvite
AW3EJL1462
Types de publication
Journal Article
Langues
eng
por
Sous-ensembles de citation
IM
Pagination
200-206Références
Nat Rev Nephrol. 2016 Sep;12(9):519-33
pubmed: 27452364
Am J Physiol. 1993 Dec;265(6 Pt 2):F784-91
pubmed: 8285211
Int J Antimicrob Agents. 2002 Jun;19(6):488-98
pubmed: 12135839
Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1699-1708
pubmed: 28830863
J Endourol. 1995 Feb;9(1):51-4
pubmed: 7780431
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
JAMA. 1977 Oct 3;238(14):1519-23
pubmed: 578220
World J Urol. 2013 Oct;31(5):1141-5
pubmed: 22373698
Urology. 2012 Oct;80(4):776-9
pubmed: 22921696
Eur Urol. 2012 Jul;62(1):160-5
pubmed: 22498635
Am J Med. 1995 Jan;98(1):50-9
pubmed: 7825619
Urolithiasis. 2017 Apr;45(2):185-192
pubmed: 27240693
Arch Ital Urol Androl. 2016 Oct 05;88(3):208-211
pubmed: 27711095
Biomed Pharmacother. 2017 Dec;96:361-370
pubmed: 29028588
Eur Urol. 2015 Apr;67(4):750-63
pubmed: 25454613
J Bone Miner Res. 1987 Jun;2(3):215-20
pubmed: 3455168
Medicine (Baltimore). 1983 Jan;62(1):44-51
pubmed: 6337315
J Urol. 2005 Mar;173(3):848-57
pubmed: 15711292
Scand J Urol Nephrol Suppl. 1986;98:1-71
pubmed: 3026032
Urol Clin North Am. 1981 Jun;8(2):265-76
pubmed: 7268961
Kidney Int. 1990 Oct;38(4):728-35
pubmed: 2232510
Kidney Int. 1994 Jun;45(6):1722-30
pubmed: 7933820
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):267-72
pubmed: 15625112
Br J Anaesth. 2014 Sep;113(3):424-32
pubmed: 24727705
World J Urol. 1999 Oct;17(5):308-15
pubmed: 10552150
J Endourol. 2016 Oct;30(10):1095-1098
pubmed: 27479686
J Urol. 1995 Mar;153(3 Pt 1):584-7
pubmed: 7861487
N Engl J Med. 1992 Oct 15;327(16):1141-52
pubmed: 1528210
Urology. 1986 Nov;28(5):377-80
pubmed: 3787896
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Scand J Urol Nephrol. 2000 Feb;34(1):36-41
pubmed: 10757268
Can Urol Assoc J. 2010 Jun;4(3):209-10
pubmed: 20514287